|
Cancer
Type |
Effect
of Selenium |
Source |
| Prostate cancer |
63% fewer cases of prostate cancer for
4.5 years supplementation |
Clark et al. 1996 |
| Prostate cancer |
Participants in the lower quintile of Se status
were three times more likely to develop advanced cancer |
Yoshizawa et al. 1998 |
| Prostate cancer |
Higher Se was associated with a lower risk of
prostate cancer, with a
four
to five
fold increased risk |
Brooks et al. 2001 |
| Prostate cancer |
significant decrease in prostate-specific
antigen, suggesting a protective effect against prostate cancer
with Se supplementation |
El-Bayoumy et al. 2002 |
| Prostate cancer |
48% fewer cases of prostate cancer for
10 years supplementation |
Duffield-Lillico et al. 2002 |
|
| Lung cancer |
reduced risk of lung cancer |
Knekt et al. 1990, 1991, 1998 |
| Lung cancer |
46% fewer cases of lung cancer for
4.5 years supplementation |
Clark et al. 1996 |
| Lung cancer |
rates of cancer were only half as high among
those receiving supplement |
Blot, 1997 |
| Lung cancer |
29% fewer cases of lung cancer for
10 years supplementation |
Duffield-Lillico et al. 2002 |
|
| Oesophageal cancer |
cumulative death rates were 8% lower among
individuals receiving Se |
Li et al. 1993 |
| Oesophageal cancer |
Se produced a modest protective effect against
oesophageal cancer mortality |
Taylor et al. 1994 |
| Oesophageal cancer |
great reduction in cancer apparent about two
years into supplementation |
Blot, 1997 |
| Oesophageal cancer |
significant inverse associations between baseline
serum Se and death from oesophageal squamous carcinoma |
Wei et al. 2004 |
|
| Gastric cardia cancer |
cumulative death rates were 8% lower among
individuals receiving Se |
Li et al. 1993 |
| Gastric cardia cancer |
significant inverse associations between baseline
serum Se and death from
gastric squamous cancer |
Wei et al. 2004 |
|
| Stomach cancer |
reduced risk of stomach cancer |
Knekt et al. 1990, 1991 |
| Stomach cancer |
significant reductions in stomach
cancer mortality |
Blot et al. 1993 |
| Stomach cancer |
great reduction in cancer apparent about two
years into supplementation |
Blot, 1997 |
|
|
Colon
cancer |
58% fewer cases of colon cancer for
4.5 years supplementation |
Clark et al. 1996 |
|
Colon
cancer |
53% fewer cases of colon cancer for
10 years supplementation |
Duffield-Lillico et al. 2002 |
|
|
Large bowel cancer |
the observed incidence of meta-chronous adenomas
was 5.6% in the supplemented group vs. 11% (control) |
Bonelli et al. 1998 |
|
|
Liver cancer |
Se supplementation resulted in a drop of primary
liver cancer incidence to almost one half (27.2% vs. 50.4%) |
Yu et al. 1991 |
|
Hepatocellular carcinoma
(liver cancer) |
reduced hepatocellular carcinoma by
35% over a period of six years |
Yu et al. 1997 |
Hepatocellular carcinoma
(liver cancer) |
significant inverse association between
Se levels in plasma and development
of disease |
Yu et al. 1999 |
|
|
Pancreas cancer |
reduced risk of pancreas cancer |
Knekt et al. 1990, 1991 |
|
|
Total cancer |
Subjects receiving Se showed 50% lower total
cancer mortality and 63% lower total cancer incidence for a mean
of 4.5 years
of supplementation |
Clark et al. 1996 |
|
Total cancer |
total mortality and cancer mortality were
significantly reduced |
Blot, 1997 |
